​REGISTRATION CLOSES END OF DAY MARCH 20TH.

​Join us at the new Boston Nucleate HQ for an evening of conversation and networking with biotech founders, investors, and clinical development leaders exploring how global dynamics are reshaping early-stage trial strategy.

​As the clinical research landscape continues to evolve, U.S. biotech companies are increasingly reconsidering where and how early-stage trials are conducted. Expanding global trial capacity, rising expectations from investors around development timelines, and the growing influence of regions such as China on trial scale and speed are prompting companies to rethink traditional development pathways.

​These shifting dynamics are also pushing companies to evaluate alternative geographic strategies for generating high-quality clinical data efficiently. Among these emerging options, Australia has become an increasingly important location for early-phase trials due to its regulatory framework, trial start-up timelines, and globally recognized data.

​Through two panel discussions and audience Q&A, speakers will explore how U.S. biotechs are reframing trial strategy in a changing global environment and why Australia is gaining attention as a faster and capital-efficient pathway for early clinical development.

​Agenda

​5:00 PM – 5:30 PM
Arrival and Open Networking

​5:30 PM – 5:40 PM
Welcome Remarks and Event Overview

​5:40 PM – 6:30 PM
Panel 1
Shifting Global Dynamics: How Biotechs Are Reframing Trial Strategy
Followed by Audience Q&A

​6:30 PM – 7:20 PM
Panel 2
Running Trials in Australia: Speed, Cost, and Global Data Acceptance
Followed by Audience Q&A

​7:20 PM – 9:00 PM
Networking Reception

​Panel 1

​Global clinical trial capacity and speed are evolving rapidly, prompting U.S. biotech companies to reassess how and where studies are conducted across development programs. This discussion examines how shifting international dynamics, including China’s growing influence in clinical research, are shaping development strategy, investor expectations, and geographic trial planning.

​Topics include:

​• How expanding global trial ecosystems, including China’s scale and efficiency, are shaping expectations around development timelines
• When geographic trial strategy becomes a board-level conversation for biotech leadership and investors
• How investors evaluate development programs that rely on different global trial regions
• How some companies are using China strategically for early proof-of-concept studies to de-risk programs before larger global trials
• What criteria a credible alternative must meet to balance speed, cost, and long-term regulatory strategy

​Panel 2

​As companies evaluate different global pathways for generating clinical data, Australia has become an increasingly attractive location for running trials efficiently while maintaining strong regulatory credibility. This panel explores how Australia’s regulatory framework, trial start-up timelines, and cost structure enable sponsors to generate globally accepted clinical data while supporting broader development strategies.

​Topics include:

​• Why Australia offers structural advantages in speed and cost efficiency for running clinical trials
• What rapid regulatory approval and trial start-up look like in practice, including a 35-day approval case study
• Achieving first participant enrollment in an average of 68.4 days
• How Australian clinical data integrates into FDA, EMA, and NMPA submissions
• The full economic picture, including direct trial costs and the 43.5 percent R&D tax rebate
• How companies sequence Australia into U.S. and global development programs without sacrificing time or data integrity

​About the Sponsor

Accelagen

​Accelagen is a globally adept, Australian-based contract research organisation (CRO) that partners with biopharmaceutical and medical device companies to accelerate clinical development and regulatory success. Using a strategic, end-to-end approach that combines clinical trial execution with regulatory planning, they help sponsors design and deliver high-quality, globally accepted data from first-in-human through later-phase studies. By working backwards from key regulatory and commercial goals, Accelagen creates tailored pathways that reduce delays, optimise efficiency, and support meaningful outcomes for human health worldwide.

​Meet up with CEO Greg Plunkett during his visit to Boston - book time here.

​About the Host

​Nucleate

​​​Nucleate is a 501(c)(3) nonprofit organization dedicated to empowering the next generation of biotech leaders. With chapters spanning 41 geographic regions and participation from over 280 academic institutions, Nucleate sparks new intellectual communities and embeds emerging talent within a global biotech community. Through open-access educational programming, Nucleate helps democratize biotech innovation — removing barriers and helping founders concentrate on building transformational technologies.

​Nucleate is not a sponsor or beneficiary of this event.

​Visit www.nucleate.xyz for more information.

​By entering this event, you consent to being photographed, filmed, and/or otherwise recorded. Your entry constitutes your consent to the use of your likeness, voice, and name in all media for promotional, marketing, or other purposes, without compensation.